Search Results - "Blatchford, Jonathan P"

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial by Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr

“…The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic…”
Get full text

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial by Biegus, Jan, Voors, Adriaan A, Collins, Sean P, Kosiborod, Mikhail N, Teerlink, John R, Angermann, Christiane E, Tromp, Jasper, Ferreira, Joao Pedro, Nassif, Michael E, Psotka, Mitchell A, Brueckmann, Martina, Salsali, Afshin, Blatchford, Jonathan P, Ponikowski, Piotr

“…Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium-glucose…”
Get full text

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial by Kosiborod, Mikhail N, Angermann, Christiane E, Collins, Sean P, Teerlink, John R, Ponikowski, Piotr, Biegus, Jan, Comin-Colet, Josep, Ferreira, João Pedro, Mentz, Robert J, Nassif, Michael E, Psotka, Mitchell A, Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan P, Salsali, Afshin, Voors, Adriaan A

“…Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of…”
Get full text

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial by Voors, Adriaan A., Damman, Kevin, Teerlink, John R., Angermann, Christiane E., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr

“…Aim The sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients…”
Get full text

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial by Tromp, Jasper, Kosiborod, Mikhail N., Angermann, Christiane E., Collins, Sean P., Teerlink, John R., Ponikowski, Piotr, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Brueckmann, Martina, Blatchford, Jonathan P, Steubl, Dominik, Voors, Adriaan A.

“…Aim The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the…”
Get full text

The win ratio method in heart failure trials: lessons learnt from EMPULSE by Pocock, Stuart J., Ferreira, João Pedro, Collier, Timothy J., Angermann, Christiane E., Biegus, Jan, Collins, Sean P., Kosiborod, Mikhail, Nassif, Michael E., Ponikowski, Piotr, Psotka, Mitchell A., Teerlink, John R., Tromp, Jasper, Gregson, John, Blatchford, Jonathan P., Zeller, Cordula, Voors, Adriaan A.

“…ABSTRACT Aims The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using the stratified win ratio approach in 530 patients with…”
Get full text

Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE by Ferreira, João Pedro, Blatchford, Jonathan P, Teerlink, John R, Kosiborod, Mikhail N, Angermann, Christiane E, Biegus, Jan, Collins, Sean P, Tromp, Jasper, Nassif, Michael E, Psotka, Mitchell A, Comin-Colet, Josep, Mentz, Robert J, Brueckmann, Martina, Nordaby, Matias, Ponikowski, Piotr, Voors, Adriaan A

“…In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with…”
Get full text

Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE by Ferreira, João Pedro, Blatchford, Jonathan P., Teerlink, John R., Kosiborod, Mikhail N., Angermann, Christiane E., Biegus, Jan, Collins, Sean P., Tromp, Jasper, Nassif, Michael E., Psotka, Mitchell A., Comin‐Colet, Josep, Mentz, Robert J., Brueckmann, Martina, Nordaby, Matias, Ponikowski, Piotr, Voors, Adriaan A.

“…Aims Patients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days…”
Get full text